%0 Journal Article
%T Current and emerging treatments for the management of myasthenia gravis
%A Sathasivam S
%J Therapeutics and Clinical Risk Management
%D 2011
%I 
%R http://dx.doi.org/10.2147/TCRM.S14015
%X rrent and emerging treatments for the management of myasthenia gravis Review (8433) Total Article Views Authors: Sathasivam S Published Date July 2011 Volume 2011:7 Pages 313 - 323 DOI: http://dx.doi.org/10.2147/TCRM.S14015 Sivakumar Sathasivam The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UK Abstract: Myasthenia gravis is an autoimmune neuromuscular disorder. There are several treatment options, including symptomatic treatment (acetylcholinesterase inhibitors), short-term immunosuppression (corticosteroids), long-term immunosuppression (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid acting short-term immunomodulation (intravenous immunoglobulin, plasma exchange), and long-term immunomodulation (thymectomy). This review explores in detail these different treatment options. Potential future treatments are also discussed.
%K acetylcholinesterase inhibition
%K immunosuppression
%K immunomodulation
%K thymectomy
%U https://www.dovepress.com/current-and-emerging-treatments-for-the-management-of-myasthenia-gravi-peer-reviewed-article-TCRM